Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals

Clinical Infectious Diseases

Volumn 51, Issue 9, 2010, Pages 1090-1098

  Rotger, Margalida ^a   Gsponer, Thomas ^c   Martinez, Raquel ^a   Taffé, Patrick ^b,j   Elzi, Luigia ^e,j   Vernazza, Pietro ^f,j   Cavassini, Matthias ^b,j   Bernasconi, Enos ^g,j   Hirschel, Bernard ^h,l   Furrer, Hansjakob ^d,k   Weber, Rainer ^i,j   Ledergerber, Bruno ^i,l   Egger, Matthias ^c,j   Telenti, Amalio ^a,j   Tarr, Philip E ^e   Battegay, M ^j   Boni J ^j   Burgisser Ph ^j   Calmy, A ^j   Cattacin, S ^j   Dubs, R ^j   Fischer, M ^j   Flepp, M ^j   Fontana, A ^j   Francioli, P ^j   Fux, C ^j   Gorgievski, M ^j   Gunthard H ^j   Hirsch, H ^l   Hosli I ^l   Kahlert, Ch ^l   Kaiser, L ^l   Karrer, U ^l   Kind, C ^l   Klimkait, Th ^l   Martinetti, G ^l   Martinez, B ^l   Muller N ^l   Nadal, D ^l   Opravil, M ^l   Paccaud, F ^l   Pantaleo, G ^l   Rauch, A ^l   Regenass, S ^l   Rickenbach, M ^l   Rudin, C ^j   Schmid, P ^j   Schultze, D ^j   Schupbach J ^j   Speck, R ^j   Trkola, A ^j   Yerly, S ^j   more..

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^h UNIVERSITY HOSPITAL   (Switzerland)

ⁱ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^j Clinical and Laboratory Committee ^*  (Switzerland)

^k Clinical and Laboratory Committee   (Switzerland)

^l Data Center   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; FOLLOW UP; GENETIC RISK; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTI-HIV AGENTS; DIABETES MELLITUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HUMANS; INCIDENCE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SWITZERLAND;

EID: 77958529496     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656630     Document Type: Article

References (41)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
2. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84:1932-1937.
3. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
4. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-2512. (Pubitemid 47037350)
5. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse-transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19:1375-1383.
6. De WS, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31:1224-1229.
7. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:298-302.
8. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45:111-119.
9. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007; 21:1739-1745.
10. Souren NY, Paulussen AD, Loos RJ, et al. Anthropometry, carbohydrate and lipid metabolism in the East Flanders Prospective Twin Survey: heritabilities. Diabetologia 2007; 50:2107-2116.
11. Bouatia-Naji N, Rocheleau G, Van LL, et al. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 2008; 320:1085-1088.
12. Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39:977-983.
13. Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316(5829):1331-1336.
14. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316:1341-1345.
15. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445:881-885.
16. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 2007; 39:770-775.
17. Unoki H, Takahashi A, Kawaguchi T, et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 2008; 40:1098-1102.
18. Yasuda K, Miyake K, Horikawa Y, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008; 40:1092-1097.
19. Zeggini E, Weedon MN, Lindgren CM, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316:1336-1341.
20. Zeggini E, Scott LJ, Saxena R, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40:638-645.
21. SCHS home page. http://www.shcs.ch. Published 2000. Updated 31 August 2010. Accessed 13 September 2010.
22. Rotger M, Bayard C, Taffe P, et al. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circ Cardiovasc Genet 2009; 2:621-628.
23. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26:3160-3167.
24. Young J, Glass TR, Bernasconi E, et al. Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. J Clin Epidemiol 2009; 62:632-641.
25. Agresti A. Categorical data analysis. New York, NY: Wiley, 2002.
26. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359:2220-2232.
27. Team DC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2009.
28. Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447:661-678.
29. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38:320-323.
30. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184. (Pubitemid 40720744)
31. Aulchenko YS, Ripatti S, Lindqvist I, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009; 41:47-55.
32. Kathiresan S, Voight BF, Purcell S, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009; 41:334-341.
33. Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008; 359:2208-2219.
34. Cauchi S, Meyre D, Durand E, et al. Post genome-wide association studies of novel genes associated with type 2 diabetes show gene-gene interaction and high predictive value. PLoS One 2008; 3:e2031.
35. Tarr PE, Rotger M, Telenti A. Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics. Pharmacogenomics 2010; 11:587-594.
36. Arnedo M, Taffe P, Sahli R, et al. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics 2007; 17:755-764.
37. Tarr PE, Taffe P, Bleiber G, et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005; 191:1419-1426.
38. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461:747-753.
39. Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010; 42:105-116.
40. Orho-Melander M, Melander O, Guiducci C, et al. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 2008; 57:3112-3121.
41. Sabatti C, Service SK, Hartikainen AL, et al. Genome-wide association analysis of metabolic traits in a birth cohort froma founder population. Nat Genet 2009; 41:35-46.